Company intelligence
Phagenesis
Retrain The Brain. Restore Swallowing Control.
Medical Device
Manchester, GB
79 employees
Founded 2007
4 public signals
About Phagenesis
Phagenyx® is the first and only clinically validated neuromodulation system that utilizes pharyngeal electrical stimulation (PES) to improve swallowing safety and efficiency to accelerate recovery from post-stroke dysphagia. Supported by 30+ publications and designed for real-world care, Phagenyx enables early intervention, resulting in a 6-day faster return to oral nutrition, >2x improvement in swallowing safety, and 8 fewer days in the hospital.
Verified activity
Signals from Phagenesis
4 published signals
Presence & Recognition
Phagenesis is hosting the Phagenesis Symposium on Post-Stroke-Dysphagia at the DSG 2026 conference in Berlin on September 10, 2026.
Reported by Michael Schubert
Products & Services
Phagenesis introduced Phagenyx, a technology targeting neural pathways involved in swallowing to address neurogenic dysphagia.
Reported by Michael Schubert
Research & Knowledge
Phagenesis announced that the AHA/ASA stroke rehabilitation guidelines now recognize pharyngeal electrical stimulation (PES) as a therapy to improve swallowing function in patients with severe dysphagia post-stroke.
Reported by Phagenesis
Products & Services
Phagenesis offers Phagenyx, a product designed to restore neurological control of swallowing, reduce aspiration risk, and accelerate recovery in patients with severe dysphagia post-stroke.
Reported by Phagenesis